Comprehensive Understanding of Glioblastoma Molecular Phenotypes: Classification, Characteristics, and Transition
Overview
Authors
Affiliations
Among central nervous system-associated malignancies, glioblastoma (GBM) is the most common and has the highest mortality rate. The high heterogeneity of GBM cell types and the complex tumor microenvironment frequently lead to tumor recurrence and sudden relapse in patients treated with temozolomide. In precision medicine, research on GBM treatment is increasingly focusing on molecular subtyping to precisely characterize the cellular and molecular heterogeneity, as well as the refractory nature of GBM toward therapy. Deep understanding of the different molecular expression patterns of GBM subtypes is critical. Researchers have recently proposed tetra fractional or tripartite methods for detecting GBM molecular subtypes. The various molecular subtypes of GBM show significant differences in gene expression patterns and biological behaviors. These subtypes also exhibit high plasticity in their regulatory pathways, oncogene expression, tumor microenvironment alterations, and differential responses to standard therapy. Herein, we summarize the current molecular typing scheme of GBM and the major molecular/genetic characteristics of each subtype. Furthermore, we review the mesenchymal transition mechanisms of GBM under various regulators.
Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.
DAprile S, Denaro S, Gervasi A, Vicario N, Parenti R Front Cell Dev Biol. 2025; 13:1535073.
PMID: 40078366 PMC: 11897528. DOI: 10.3389/fcell.2025.1535073.
Markov A, Moralev A, Odarenko K Biomedicines. 2025; 13(1).
PMID: 39857717 PMC: 11761231. DOI: 10.3390/biomedicines13010133.
Bullatine A suppresses glioma cell growth by targeting SIRT6.
Wang Z, Zhu Y, Luo C, Zhang F, Zhao J, Fu C Heliyon. 2025; 11(1):e41440.
PMID: 39845013 PMC: 11750491. DOI: 10.1016/j.heliyon.2024.e41440.
Lenda B, Zebrowska-Nawrocka M, Balcerczak E Biomedicines. 2024; 12(10).
PMID: 39457549 PMC: 11504030. DOI: 10.3390/biomedicines12102236.
Rahman M, Ali M Cancers (Basel). 2024; 16(17).
PMID: 39272834 PMC: 11394361. DOI: 10.3390/cancers16172975.